Prevention of hepatitis B virus infection in the United States: A pediatric perspective

Pediatric Infectious Disease Journal

Volumn 11, Issue 10, 1992, Pages 866-874

  West, David J ^a   Margolis, Harold S ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Hepatitis B; Prevention

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; VIRUS DNA;

ADOLESCENT; AGE; ANTIBODY PRODUCTION; CHILD; CHRONIC HEPATITIS; COST; DRUG ABUSE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFANT; INFECTION RISK; LIVER CARCINOGENESIS; PEDIATRICS; PERINATAL INFECTION; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; SCREENING; SEXUAL TRANSMISSION; SYMPTOM; UNITED STATES; VACCINATION; VIRUS TRANSMISSION;

CHILD; FORECASTING; HEPATITIS B; HUMAN; UNITED STATES; VACCINATION;

EID: 0026667677     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/00006454-199210000-00012     Document Type: Article

References (75)

1. Hoofnagle JH, Di Bisceglie AN. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis 1991;11:73-83.
2. Jenison SA, Lemon SM, Baker LN, et al. Quantitative analysis of hepatitis B virus in saliva and semen of chronically infected homosexual men. J Infect Dis 1987;156:299.
3. Francis DP, Favero MS, Maynard JE. Transmission of hepatitis B virus. Semin Liver Dis 1981;1:27-32.
4. Cancio-Bello TP, de Medina M, Shorey J, et al. An institutional outbreak of hepatitis B related to a human biting carrier. J Infect Dis 1982;164:652-6.
5. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
6. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991; 11:84-92.
7. Maynard JE, Kane MA, Hadler SC: Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Programme on Immunization. Rev Infect Dis 1989;11(Suppl 3):s574-8.
8. Margolis HS, Schatz GC, Kane MA: Development of recommendations for control of hepatitis B virus infections: the role of cost analysis. Vaccine 1990;8(Suppl.):s81-5.
9. Centers for Disease Control. Protection against viral hepatitis: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1990;39(No. RR-2):1-25.
10. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
11. Sinatra FR, Shah P, Weissman JY, et al. Perinatal transmitted acute icteric hepatitis B in infants born to hepatitis B surface antigen-positive and anti-hepatitis Be-positive carrier mothers. Pediatrics 1982;70:557-9.
12. Delaplane D, Yogev R, Crussi F, et al. Fatal hepatitis B in early infancy: the importance of identifying HbsAg-positive pregnant women and providing immunoprophylaxis to their newborns. Pediatrics 1983;72:176-80.
13. McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen positive Alaska native carriers. Arch Intern Med 150:1051-4.
14. Beasley RP, Hwang LY. Epidemiology of hepatocellular carcinoma. In: Vyas ON, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York: Grune & Stratton, 1984:204-24.
15. Boss LP, Bender TR, Schreeder MT, et al. Hepatitis B testing in the families and villages of five young Eskimos with primary hepatocellular carcinoma. Am J Epidemiol 1981;114:95-101.
16. Yu MC, Tong M.J, Coursaget P, et al. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst 1990;82:1038-41.
17. Stevens CE, Neurath RA, Beasley RP, et al. HBeAg and anti-HBs detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 1979; 3:237-41.
18. Xu ZY, Liu CB, Francis DP, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985;76:713-8.
19. Lee SD, Lo KJ, Wu JC, et al. Prevention of maternal-infant hepatitis B transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 1986;6:369-73.
20. Lelie PN, Ip HMH, Reesink HW, et al. Prevention of the hepatitis B virus carrier state in infants of mothers with high and low serum levels of HBV-DNA. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:753-6.
21. Terazawa S, Kojima M, Yamanaka T, et al. Hepatitis B virus mutants with pre-core region defects in two babies with fulminant hepatitis and their mothers positive for antibody to hepatitis B e antigen. Pediatr Res 1991;29:5-9.
22. Beasley RP, Hwang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983:147:185-90.
23. Marinier E, Barrois V, Larouze B, et al. Lack of perinatal transmission of hepatitis B virus infection in Senegal, West Africa. J Pediatr 1985;106:843-9.
24. Schreeder MT, Bender TR, McMahon BJ, et al: Prevalence of hepatitis B in selected Alaskan Eskimo villages. Am J Epidemiol 1983;118:543-9.
25. Wong DC, Purcell RH, Rosen L. Prevalence of antibody to hepatitis A and hepatitis B viruses in selected populations of the South Pacific. Am J Epidemiol 1979;110:227-36.
26. Franks AL, Berg CJ, Kane MA, et al: Hepatitis B virus infection among children born in the United States to Southeast Asian refugees. N Engl J Med 1989;321:1301-5.
27. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics 1992;89:269-73.
28. McQuillan GM, Townsend TR, Fields HA, et al. The seroepi-demiology of hepatitis B virus in the United States, 1976-80. Am J Med 1989;87(Suppl. 3A):s5-10.
29. Petersen NJ, Barrett DH, Bond WW, et al. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol 1976;32: 572-4.
30. Alter MJ, Hadler SC, Margolis HS, et al: The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies. JAMA 1990;263:1218-22.
31. Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am 1990;74: 1529-41.
32. Alter MJ, Coleman PJ, Alexander WJ, et al. The importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis in the United States. JAMA 1989;262: 1201-5.
33. Wang EEL, King S, Goldberg E, et al. Hepatitis B and human immunodeficiency virus infection in street youth in Toronto, Canada. Pediatr Infect Dis J 1991;10:130-3.
34. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
35. Utili R, Sagnelli E, Galanti B, et al. Prolonged treatment of children with chronic hepatitis B with recombinant alpha-2a-interferon: a controlled, randomized study. Am J Gastroenterol 1991;86:327-30.
36. Hilleman MR, Buynak E, McAleer WJ, et al. Hepatitis A and hepatitis B vaccines. In: Szmuness W, Alter HJ, Maynard JE, eds. Viral hepatitis: 1981 international symposium. Philadelphia: Franklin Institute Press, 1982:385-97.
37. McAleer WJ, Buynak EB, Maigetter RZ, et al. Human hepatitis B vaccine from recombinant yeast. Nature 1984;307:178-80.
38. Petre J, Van Wijnendaele F, De Neys B, et al. Development of hepatitis B vaccine from transformed yeast cells. Postgr Med J 1987;63(Suppl. 2):73-81.
39. Andre FE. Summary of safety and efficacy data on a veast-derived hepatitis B vaccine. Am J Med 1989;87(Suppl. 3A):sl4-20.
40. West DJ. Clinical experience with hepatitis B vaccines. Am J Infect Control 1989;17:172-80.
41. Stevens CE, Taylor PE, Tong MJ. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987; 257:2612-6.
42. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 1980;303: 833-41.
43. Francis DP, Hadler SC, Thompson SE, et al. Prevention of hepatitis B with vaccine. Report from the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982;97:362-6.
44. Yeoh EK, Chang WK, Ip LS, et al. A comparative study of recombinant versus plasma vaccine in high risk infants [Abstract]. J Med Virol 1987;21:101A.
45. Poovorawan Y, Sanpavat S, Pongpunlert W, et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990; 8(Suppl.):s56-9.
46. Pongpipat D, Suvatte V, Assateerawatts A. Hepatitis B immunization in high risk neonates born from HBsAg positive mothers: comparison between plasma derived and recombinant DNA vaccine. Asian Pacific J Allergy Immunol 1989;7:37-40.
47. Shaw FE, Graham DJ, Guess HA, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination: experience of the first three years. Am J Epidemiol 1988;127:337-52.
48. McQuillan GM, Townsend TR, Johannes CB, et al. Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity and predictive value of the recommended screening questions to detect high-risk women in an obstetrics population. Am J Epidemiol 1987;126:484-91.
49. Jonas MM, Schiff ER, O’Sullivan MJ, et al. Failure of the Centers for Disease Control criteria to identify hepatitis B infection in a large municipal obstetrical population. Ann Intern Med 1987;107:335-7.
50. Kumar ML, Dawson NV, McCullough AJ, et al. Should all pregnant women be screened for hepatitis B. Ann Intern Med 1987;107:273-7.
51. Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee. Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. MMWR 1988; 37:341-6, 351.
52. Arevalo JA, Washington E. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA 1988; 259:365-9.
53. Shapiro CN, Margolis HS. Impact of hepatitis B virus infection on women and children. Infect Dis Clin North Am 1992;6:75-96.
54. Szmuness W, Harley EJ, Prince AM: Intrafamilial spread of asymptomatic hepatitis B. Am J Med Sci 1975;270:293-304.
55. Bernier RH, Sampliner R, Gerety R, et al: Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection. Am J Epidemiol 1982;116:199-211.
56. Public Health Foundation. New funding to help prevent perinatal transmission of hepatitis B. Public Health Macro View 1990;3:3-2.
57. West DJ. Perinatal hepatitis B prevention program. In: 25th National Immunization Conference Proceedings; 1991, June 10 to 13, Washington, DC. Atlanta: Centers for Disease Control, 1992:53-5.
58. Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. In: Remington J, Swartz MC, eds. Current clinical topics in infectious diseases 1992;12:282-308.
59. World Health Organization. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull WHO 1988; 66:443-55.
60. The Gambia Hepatitis Study Group. Hepatitis B vaccine in the expanded programme of immunization: the Gambian experience. Lancet 1989;1:1057-60.
61. Gust ID, Ruff TA, Sutanto A, et al. Obstacles influencing delivery of hepatitis B vaccine in developing countries: the Lomhok experience. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:708-12.
62. Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisorv Committee (ACIP). MMWR 1991;40(No. RR-13).
63. Lo KJ, Lee SD, Tsai YT, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBeAg-positive HBsAg-carrier mothers. Hepatology 1988;8:1647-50.
64. Hwang LY, Lee CY, Beasley RP. Five year follow-up of HBV vaccination with plasma-derived vaccine in neonates: evaluation of immunogenicity and efficacy against perinatal transmission. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: William & Wilkins, 1991:759-61.
65. Coursaget P, Yvonnet B, Chotard J, et al. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986;2:1143-5.
66. McMahon BJ, Rhoades ER, Heyward WL, et al. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives. Lancet 197;2: 1134-6.
67. Greenberg DP, Vadheim CM, Marcy SM, et al. Safety and immunogenicity of two recombinant hepatitis B vaccines given to 5,000 infants as part of routine immunization at 2, 4, and 6 months of age. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991, Abstract 1290:314.
68. Seto D, Diwan A, Hesley T, et al. Hepatitis B vaccine alternative vaccination schedules in healthy babies of noncarrier mothers. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstract 1104. 1991:283.
69. Hadler SC, Monzon MA, Lugo DR, et al. Effect of timing of hepatitis B vaccine dose on response to vaccine in Yucpa Indians. Vaccine 1989;7:106-10.
70. Jilg W, Schmidt S, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989;160:766-9.
71. Heyward WL, Bender TR, McMahon BJ, et al. The control of hepatitis B virus infection with vaccine in Yupik Eskimos: demonstration of safety, immunogenicity and efficacy under field conditions. Am J Epidemiol 1985;121:914-23.
72. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989;261:2362-6.
73. Krugman S, Davidson M. Hepatitis B vaccine: prospects for duration of immunity. Yale J Biol Med 1987;60:333-8.
74. Moyes CD, Milne A, Waldon J. Very low dose hepatitis B vaccination in the newborn: anamnestic response to a booster at four years. J Med Virol 1990;30:216-8.
75. Committee on Infectious Diseases—American Academy of Pediatrics. Universal hepatitis B immunization. Pediatrics 1992; 89:795-800.